Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-term assessment of safety, tolerability, and effectiveness of subcutaneous efgartigimod PH20 in adults with generalized myasthenia gravis: final findings from the phase 3 open-label extension study (ADAPT-SC+)

  • By

  • Andreas Meisel

  • Carlo Antozzi

  • Ratna Bhavaraju-Sanka

  • Jan L. De Bleecker

  • Wan-Yi Huang

  • Rosa Hermina Jimenez

  • Fien M. Verhamme

  • Ming Jiang

  • Li Liu

  • Denis Korobko

  • Anna Kostera-Pruszczyk

  • Kimiaki Utsugisawa

  • Jan J. G. M. Verschuuren

  • Tuan Vu

  • Heinz Wiendl

  • James F. Howard

  • August 21, 2026

Share

  • 1

    Efgartigimod PH20 SC demonstrated long-term safety and tolerability in adults with generalized myasthenia gravis during the ADAPT-SC+ study.

  • 2

    The study included 180 participants who received at least one dose of efgartigimod PH20 SC, with a mean treatment duration of 2.6 years.

  • 3

    Treatment-emergent adverse events occurred in 93.9% of participants, with injection site reactions being the most common.

  • 4

    Clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living scores was achieved by over 94% of participants.

  • 5

    The study supports the efficacy of individualized dosing schedules for efgartigimod PH20 SC without new safety concerns.

Original Source(s)

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)

  • by Andreas Meisel, Carlo Antozzi, Ratna Bhavaraju-Sanka, Jan L. De Bleecker, Wan-Yi Huang, Rosa Hermina Jimenez, Fien M. Verhamme, Ming Jiang, Li Liu, Denis Korobko, Anna Kostera-Pruszczyk, Kimiaki Utsugisawa, Jan J. G. M. Verschuuren, Tuan Vu, Heinz Wiendl, James F. Howard

  • August 21, 2026

Related Content

Correction: CTE-type tau filaments in Alzheimer’s disease with co-morbid LATE-NC

Neuroprognostication after cardiac arrest: time-anchored reassessment and uncertainty around zero false positives

FDA approves tau PET imaging agent

The F18-labeled agent is indicated for brain PET imaging to identify tau neurofibrillary tangle pathology.